KA
NWBO

KLCM Advisors’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

KLCM Advisors’s Portfolio NWBO Stock Details NWBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,000
Closed -$2.4K – 273
2025
Q3 		$2.4K Hold
10,000
– – ﹤0.01% 175
2025
Q2 		$2.4K Hold
10,000
– – ﹤0.01% 174
2025
Q1 		$2.28K Hold
10,000
– – ﹤0.01% 173
2024
Q4 		$2.75K Hold
10,000
– – ﹤0.01% 171
2024
Q3 		$3.2K Hold
10,000
– – ﹤0.01% 166
2024
Q2 		$4.27K Buy
+10,000
New +$4.27K ﹤0.01% 156

Other funds holding NWBO

VWA
VSM Wealth Advisory Hunt Valley, Maryland $376M AUM 21.56% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $930M AUM 16.14% 1-Year Est. Return
EFG
Ethos Financial Group King Of Prussia, Pennsylvania $1.37B AUM 19.43% 1-Year Est. Return
WJWM
Williams Jones Wealth Management New York $8.14B AUM 19.32% 1-Year Est. Return
AMG
Advisors Management Group La Crosse, Wisconsin $549M AUM 29.35% 1-Year Est. Return

KLCM Advisors's NWBO Position: Q4 2025 in Review

KLCM Advisors sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2025, closing a stake of 10,000 shares — an estimated $2.4K sold.

KLCM Advisors first reported a position in NWBO in Q2 2024 and held it in 6 quarters. The position peaked at $4.27K in Q2 2024. 7 funds tracked by Wall St. Rank hold NWBO as of Q4 2025.

  • KLCM Advisors reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2025 after selling out during the quarter.
  • KLCM Advisors sold 10,000 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2025, an estimated $2.4K.
  • KLCM Advisors first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2024 and held it in 6 quarters.
  • KLCM Advisors's Northwest Biotherapeutics, Inc. Common stock position peaked at $4.27K in Q2 2024.
  • 7 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2025.

Based on KLCM Advisors's 13F filing for Q4 2025, filed 4 Feb 2026.